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Introduction
============

Pre-eclampsia and eclampsia are among the leading causes of maternal and neonatal morbidity and mortality.[@ref1] Despite growing knowledge of the pathophysiology of pregnancy induced hypertensive disorders, no preventive measures have been shown to be effective.[@ref2] The underlying cause of pre-eclampsia/eclampsia is thought to be abnormal placentation, characterised by defective invasion of trophoblast cells and remodelling of the uterine vasculature,[@ref3] resulting in reduced utero-placental perfusion, which leads to activation of mechanisms promoting maternal vasoconstriction and activation or damage of endothelial cells.[@ref4] The endothelium is believed to be a primary target of mediators generated by the placenta. Damage is amplified by other factors such as reactive oxygen species.[@ref5]

Nitric oxide is a potent endothelium derived vasodilator,[@ref6] and defective synthesis of nitric oxide has been documented in pre-eclampsia.[@ref7] The main site of production of nitric oxide is nitric oxide synthase in endothelial cells, which uses circulating L-arginine as a substrate. Hence, the local availability of this amino acid may be critical to the endothelial adaptive regulatory mechanisms opposing the vasoconstrictors in pre-eclampsia. L-arginine is considered to be a semi-essential amino acid because under increased demands endogenous synthesis is not sufficient to fulfil requirements.[@ref8] Moreover, pregnancy has been reported to be a state of relative arginine deficiency,[@ref7] imposed by the increased formation of nitric oxide, supporting the adaptive vasodilatation of pregnancy, and use of L-arginine by the fetus.[@ref9] Pre-eclampsia is also associated with increased concentrations of factors that inhibit nitric oxide production. Concentrations of asymmetric dimethyl arginine, a competitive inhibitor of nitric oxide synthase, are raised in women with pre-eclampsia.[@ref10] Concentrations of soluble fms-like tyrosine kinase 1, which antagonises vascular endothelial growth factor dependent activation of nitric oxide synthase, have also been shown to be increased in pre-eclampsia.[@ref11] Endoglin, which impairs activation of nitric oxide synthase mediated by transforming growth factor β, is also increased.[@ref12]

In the past, the role of nutrition in the development of pre-eclampsia has been a subject of considerable discussion. Although little evidence exists to show that dietary manipulations can prevent pre-eclampsia, the notion that they might moderate the secondary features of the syndrome remains in favour.[@ref13] Substantial experimental data in animals and humans indicate that L-arginine could have a beneficial effect on haemodynamics.[@ref14] [@ref15] [@ref16] Of particular note, an expanding literature documents that administration of L-arginine improves vascular function in people with atherosclerosis and peripheral vascular disease.[@ref17] [@ref18] [@ref19] [@ref20] The oral administration of L-arginine to patients with cardiovascular disease has not been associated with any significant adverse side effects. This includes previous reports in the literature of use of L-arginine in pregnant women. Facchinetti et al and Neri et al infused L-arginine into women whose pregnancies were complicated by intrauterine growth retardation and reported reduced myometrial activity.[@ref21] [@ref22] These observations raised the possibility that supplemental L-arginine in the diet could provide a source of substrate for nitric oxide synthesis during pregnancy, which could promote vasodilatation. More clinical studies are needed in this area because we have limited experience in the use of L-arginine and other nitric oxide donators for preventing pre-eclampsia, as stated in the Cochrane review by Meher and Duley.[@ref23] On the other hand, evidence of endothelial damage mediated by reactive oxygen species has been proposed as another mechanism of endothelial damage in pre-eclampsia.[@ref24] [@ref25] [@ref26] Consequently, antioxidants have been proposed as prophylactic agents for pre-eclampsia and several trials with antioxidants including vitamin C and tocopherols in pre-eclampsia have been published.[@ref27] [@ref28] [@ref29] At the time this clinical trial was started, insufficient evidence existed for us to discard the use of antioxidants for prevention of pre-eclampsia. However, recent trials and Cochrane reviews do not support the use of antioxidants for this purpose.[@ref30] [@ref31] We did a three arm clinical trial to test the hypothesis that a combination of L-arginine and antioxidant supplementation would reduce the risk of pre-eclampsia in a high risk population in Mexico City.

Methods
=======

Study participants
------------------

We enrolled pregnant women between 14 and 32 weeks of gestation at high risk of pre-eclampsia who were receiving prenatal care at the Instituto Nacional de Perinatologia Isidro Espinosa de los Reyes in Mexico City between January 2001 and December 2005. We included patients at increased risk of pre-eclampsia, which we defined as either a personal history of pre-eclampsia or pre-eclampsia in a first degree relative. Eligible participants agreed to have their prenatal care and delivery at the institution and provide informed consent. We excluded patients with multiple gestation, known major fetal anomalies (as defined by ultrasound studies by the fetal medicine department), diabetes mellitus or gestational diabetes, pre-existing hypertension, pre-existing renal disease, collagen vascular disease, cancer or strong family history of cancer in first degree relatives, and pre-existing maternal disease needing drug treatment. We excluded women with type 2 diabetes, cancer, or a strong family history of cancer because the angiogenic actions of vascular endothelial growth factor are thought to be mediated, in part, by nitric oxide.[@ref32] All women were screened for gestational diabetes at week 14 and again at week 24 of gestation, according to the institutional protocol. We decided in advance that if a woman was diagnosed as having gestational diabetes after randomisation she would discontinue taking bars because of the aforementioned safety concerns. However, we included such women in the data analysis. We excluded patients with autoimmune disease because peroxynitrites have been implicated in the pathogenesis of tissue damage in autoimmune disease.

Recruitment and randomisation
-----------------------------

Staff of the department of obstetrics reviewed prenatal records to identify patients who might qualify for the study. A history of pre-eclampsia was confirmed by review of the patient's records, and a family history of pre-eclampsia was based on patients' self report. Gestational age was assessed by last menstrual period and confirmed by a first trimester ultrasound evaluation. The protocol for recruitment included an initial visit in which suitability for randomisation was evaluated, an invitation to participate was tendered, a complete obstetric and nutritional history was taken, and written informed consent was obtained. Participants were randomly assigned to receive one of the three treatments. The principal investigator made the assignment centrally after the patient had given informed consent, by using a computer generated code in random size blocks with concealment of allocation by sealed envelopes.

Each participant in the L-arginine plus antioxidant vitamins group received two bars a day. The average consumption of L-arginine in the United States is around 5.4 g a day,[@ref8] so we decided to supplement at least 100% of this amount in the form of an available medical food (Heart Bars, Nellson Nutraceutical, CA, USA). Two Heart Bars a day deliver 6.6 g of L-arginine and antioxidant vitamins.[@ref33] Table 1[](#tbl1){ref-type="table"} shows the composition of the bars used in the study. Participants in the antioxidant vitamins alone group received two bars a day devoid of L-arginine but containing antioxidant vitamins. Participants in the placebo group received two placebo bars a day devoid of L-arginine and antioxidant vitamins.

###### 

 Composition of Heart Bar

  Compound               Content
  ---------------------- ---------
  Total fat              2.0 g
   Saturated fat         0.5 g
   Polyunsaturated fat   1.0 g
   Monounsaturated fat   0.5 g
   Trans fat             0 g
  Cholesterol            10 mg
  Sodium                 65 mg
  Potassium              100 mg
  Total carbohydrate     19 g
   Dietary fibre         1.0 g
   Sugars                12.0 g
  Protein                9.0 g
   L-arginine            3.3 g
  Vitamin C              250 mg
  Vitamin E              200 UI
  Niacin                 25 mg
  Vitamin B-6            2.0 mg
  Vitamin B-12           4.8 µg
  Folate                 200 µg

Each bar weighed 35 g and contained 534 kJ (130 kcal); bars for placebo group were devoid of L-arginine and antioxidant vitamins; bars for antioxidant vitamins group were devoid of L-arginine.

The bars were packaged in similar envelopes that made them indistinguishable by appearance, and they were flavoured such that they had the same taste irrespective of composition. The bars were packed in boxes containing a sufficient supply for five weeks of treatment. Only the principal investigator knew the group codes. We asked participants to consume bars until the day of delivery. A basal sample of blood was taken at the randomisation visit, and protein was measured in a 24 hour urine sample before participants started the consumption of bars.

Clinical follow-up
------------------

Participants were scheduled for clinical follow-up every three to four weeks. Each visit from this point included the following: (1) Arterial pressure measurement. Measurements of the arterial pressure were made according to the recommendations of the American Heart Association (AHA) using the auscultatory method with mercury sphygmomanometers.[@ref34] All staff collecting arterial pressure measurements were certified by external monitors from the AHA, who made site visits to the hospital. (2) A sample of 10 mL of venous blood was collected for determination of L-arginine concentration. Plasma was separated and maintained at −80°C until analysis. (3) Participants were instructed to obtain a 24 hour urine sample the day before the next visit. We assessed urine protein by quantification in 24 hour urine samples with an automated method (DiaSys Diagnostic Systems, Holsheim, Germany).[@ref35] (4) To measure compliance, we gave each patient a personal diary to record consumption of bars, which they brought to every appointment. We also instructed them to keep the empty envelopes of the consumed bars, which they also brought back at each appointment. (5) We offered nutritional education and assessment of nutritional status during pregnancy to all participants. We instructed them to avoid the consumption of over the counter prenatal antioxidant vitamins and asked about non-study related vitamin ingestion at each visit.

End points
----------

We defined pre-eclampsia as hypertension (systolic blood pressure ≥140 mm Hg, diastolic blood pressure ≥90 mm Hg, or both) and proteinuria (\>300 mg/24 hours) presenting after 20 weeks of gestation in women known to be previously normotensive. We defined eclampsia as non-epileptic convulsions. We defined mild pre-eclampsia as when hypertension and proteinuria were present but no evidence of systemic organ damage was detectable. Severe pre-eclampsia was detected when proteinuria was above 2.0 g/24 hours, blood pressure was ≥160/110 mm Hg, or both. We also assessed several neonatal end points, including preterm birth (born before 37 weeks of gestation), birth weight, small for gestational age (according to institutional charts), and Apgar scores.

We based the sample size calculation on consideration of all three two way comparisons (placebo *v* antioxidant vitamins alone, placebo *v* antioxidant vitamins plus L-arginine, and antioxidant vitamins plus L-arginine *v* antioxidant vitamins alone), assuming a 50% proportional reduction in pre-eclampsia in any group compared with placebo, an α error of 0.05, a β error of 0.2, and a 1:1:1 allocation ratio. We used a Bonferroni correction so that a test specific error (α) of 0.016 (0.05/3) was used for significance testing of all primary two way comparisons. We also used the α error of 0.016 in our sample size estimation. We assumed a prevalence of pre-eclampsia in the placebo group of 30% (on the basis of pilot data from our institution).

L-arginine assays
-----------------

We measured L-arginine concentrations by high performance liquid chromatography after derivatisation with the o-phthalaldehyde-ethanethiol reagent as described by Lundsjo et al.[@ref36] The derivatised samples were separated by using a reversed phase Kingsorb 3µ C18 column (Phenomenex, Torrace, CA) according to the standard method. We used peak areas for quantification of L-arginine concentrations, using an external standard as reference. We report values as µM in plasma. We monitored within assay and between assay coefficients of variation and maintained them under 3%.

Statistical analysis
--------------------

The Universidad Autonoma de Sinaloa (MAA-V) and our biostatistics group (SE and MG) did an independent analysis of the data. The analysis was based on an intention to treat principle. We compared baseline measures among the treatment groups by using analysis of variance methods and Kruskal-Wallis tests. We calculated the proportion of participants who developed pre-eclampsia in each treatment group and did an overall test of equivalence in these proportions by using a Pearson χ^2^ statistic test. We calculated absolute risk reduction and relative risk, including 95% confidence intervals, and statistical significance.[@ref37]

Results
=======

We approached 696 women (figure[](#fig1){ref-type="fig"}. We excluded 24 women because they failed to meet inclusion criteria (10 patients) or refused to participate (14 women). Six hundred and seventy-two women met our eligibility criteria and agreed to participate. Forty-four (6.5%) women had a direct relative who had developed pre-eclampsia, and they were equally distributed among the three arms in this study. Six hundred and twenty-eight women had a previous pregnancy complicated by pre-eclampsia. We allocated 222 women to the placebo group, 228 women received the L-arginine plus antioxidant vitamins bars, and 222 women received the bars with antioxidant vitamins alone. The treatment groups were well balanced with regards to baseline characteristics (table 2[](#tbl2){ref-type="table"}).

![Flow diagram of trial](vadf756783.f1_default){#fig1}

###### 

 Baseline characteristics of participants. Values are means (SD) unless stated otherwise

  Characteristic                                                                   Placebo (n=222)   L-arginine + vitamins (n=228)   Vitamins alone (n=222)   P value
  -------------------------------------------------------------------------------- ----------------- ------------------------------- ------------------------ ---------
  Age (years)                                                                      28.2 (5.1)        28.0 (6.1)                      27.6 (5.5)               0.47\*
  Gestational age at enrolment (weeks)                                             21.1 (4.7)        20.9 (4.6)                      21.1 (5.3)               0.84\*
  Previous gestation with pre-eclampsia/first degree relative with pre-eclampsia   211/11            218/10                          209/13                   0.65†
  Median (range) parity                                                            2 (1-9)           2 (1-6)                         2 (1-6)                  0.09†
  Median (range) vaginal deliveries                                                0 (0-5)           0 (0-3)                         0 (0-6)                  0.42†
  Median (range) previous caesarean sections                                       1 (0-2)           1 (0-3)                         1 (0-3)                  0.48†
  Median (range) abortions                                                         0 (0-5)           0 (0-3)                         0 (0-2)                  0.13†
  Systolic blood pressure at enrolment (mm Hg)                                     105.1 (9.8)       105.4 (8.8)                     105.6 (8.8)              0.86\*
  Diastolic blood pressure at enrolment (mm Hg)                                    68.3 (9.1)        67.2 (8.7)                      67.6 (7.9)               0.40\*
  Plasma L-arginine (µM)                                                           21.9 (8.5)        22.7 (8.3)                      21.9 (9.2)               0.52\*
  Pre-gestational body mass index                                                  26.8 (4.9)        27.5 (5.3)                      26.1 (4.1)               0.28\*
  Smoked during pregnancy                                                          5                 4                               6                        0.87†

\*Analysis of variance.

†Kruskal-Wallis test.

Clinical follow-up was similar among the women included in the analysis. All groups had a median of 5 (range 2-9) visits during the study (Kruskal-Wallis, P=0.21). Less than 5% of study visits were missed for all three groups. In terms of compliance, the placebo group consumed a mean of 1.1 (SD 0.5) bars a day, the L-arginine plus antioxidant vitamins group consumed 1.2 (0.4) bars a day, and the vitamins alone group consumed 1.1 (0.43) bars a day (analysis of variance, P=0.23). The nutritionists developed several strategies to promote compliance. Briefly, patients were instructed to mix bars with other foods such as yoghurt, gelatine, milk shakes, or fruit.

Reported side effects were significantly more frequent in the group consuming L-arginine plus antioxidant vitamins bars than in the placebo group, including nausea (P=0.019; absolute risk reduction 0.05, 95% confidence interval 0.02 to 0.08; relative risk 1.25, 1.04 to 1.51); symptoms of dyspepsia (P=0.04; 0.03, 0.01 to 0.06; 1.34, 1.02 to 1.77); dizziness (P=0.039; 0.03, 0.01 to 0.05; 1.42, 1.02 to 1.97); palpitations (P=0.019; 0.04, 0.01 to 0.07; 1.36, 1.05 to 1.76); and headache (P=0.01; 0.06, 0.03 to 0.09; 1.26, 1.06 to 1.51). None of these side effects led to a participant dropping out of the study.

One hundred and twenty-five patients discontinued their assigned treatment. However, we followed them up until the end of pregnancy and included them analytically in the group to which they were randomised. Fifty-six women decided to drop out of the study voluntarily: 18 in the placebo group, 17 in the L-arginine plus antioxidant vitamins group, and 21 in the antioxidant vitamins alone group. Sixty-nine participants discontinued the use of bars because of the development of gestational diabetes: 24 in the placebo group, 23 in the L-arginine plus antioxidant vitamins group, and 22 in the antioxidant vitamins alone group.

Primary end point
-----------------

Table 3[](#tbl3){ref-type="table"} shows the findings for the primary end point. The incidence of pre-eclampsia/eclampsia was significantly lower (χ^2^=19.41; P\<0.001) in women randomised to L-arginine plus antioxidant vitamins compared with placebo (absolute risk reduction 0.17, 0.12 to 0.21). The number needed to treat (NNT) was 5.73 (95% confidence interval 4.0 to 10.0). Women receiving antioxidant vitamins alone had an observed benefit, but this effect was not statistically significant compared with placebo (χ^2^=3.76; P=0.052; absolute risk reduction 0.07, 0.005 to 0.15; NNT 13.06, 6 to 200). The incidence of hypertensive disease was also reduced in the L-arginine plus vitamins group compared with the vitamins alone group (χ^2^=8.16; P=0.004). Adding L-arginine to antioxidant vitamins compared with vitamins alone resulted in a significant effect on absolute risk reduction (0.09, 0.05 to 0.14; NNT 10.20, 6 to 36).

###### 

 Clinical outcomes

                                          No (%)\*                      Absolute risk reduction (95%CI); relative risk (95% CI)\*                                                                                                                                  
  --------------------------------------- -------------- -------------- ----------------------------------------------------------- -- ------------------------------------------------------------- ------------------------------------------------------------- ------------------------------------------------------------
  **Primary outcome**                                                                                                                                                                                                                                              
  Pre-eclampsia or eclampsia              67 (30)        29 (13)        50 (23)                                                        0.17 (0.12 to 0.21); 0.42 (0.28 to 0.62) (χ^2^: P\<0.001)     0.07 (0.005 to 0.15); 0.74 (0.54 to 1.02) (χ^2^: P= 0.052)    0.09 (0.05 to 0.14); 0.56 (0.37 to 0.85) (χ^2^: P=0.004)
  **Secondary outcomes**                                                                                                                                                                                                                                           
  Total preterm delivery                  44 (20)        24 (11)        52 (23)                                                        0.09 (0.05 to 0.13); 0.53 (0.33 to 0.84) (χ^2^: P=0.003)      0.03 (−0.02 to 0.09); 1.18 (0.82 to 1.68) (χ^2^: P=0.419)     0.12 (−0.08 to 0.17); 0.44 (0.28 to 0.70) (χ^2^: P\<0.001)
  Spontaneous preterm delivery            13 (6)         12 (5)         15 (7)                                                         0.005 (−0.03 to 0.02); 0.89 (0.41 to 1.92) (χ^2^: P=0.631)    0.009 (−0.02 to 0.04); 1.15 (0.56 to 2.36) (χ^2^: P=0.845)    0.01 (−0.04 to 0.14); 0.77 (0.37 to 1.62) (χ^2^: P=0.386)
  Caesarean section                       152 (68.4)     155 (67.9)     148 (66.6)                                                     −0.004 (−0.67 to 0.57); 0.99 (0.87 to 1.12) (χ^2^: P=0.832)   −0.01 (−0.08 to 0.04); 0.97 (0.85 to 1.10) (χ^2^: P= 0.612)   0.01 (−0.04 to 0.75); 1.01 (0.89 to 1.15) (χ^2^: P=0.843)
  Mean (SD) gestational age at delivery   38.4 (2.2)     39.0 (1.9)     38.6 (1.9)                                                     0.65 (0.27 to 1.04)† (P=0.001)                                0.29 (−0.68 to 0.09)† (P=0.13)                                0.35 (−0.7 to 0.004)† (P=0.051)
  Sex of baby (F/M)                       115/107        117/111        110/112                                                        χ^2^: P=0.993                                                 χ^2^: P=0.704                                                 χ^2^: P=0.780
  Mean (SD) Apgar score:                                                                                                                                                                                                                                           
   1 minute                               7.8 (1.1)      8.2 (0.8)      8.0 (0.8)                                                      0.44 (0.24 to 0.64)† (P=0.000)                                0.25 (0.04 to 0.47)† (P=0.015)                                0.18 (0.01 to 0.36)† (P=0.04)
   5 minutes                              8.7 (0.7)      8.9 (0.3)      8.9 (0.3)                                                      0.21 (0.10 to 0.33)† (P=0.000)                                0.16 (0.05 to 0.46)† (P=0.007)                                0.05 (0.02 to 0.12)† (P=0.18)
  Mean (SD) neonatal weight (g)           3070.2 (470)   2988.6 (506)   2990.7 (451)                                                   81, (−15 to 179)† (P=0.1)                                     2 (−102 to 98)† (P=0.96)                                      79 (−17 to 175)† (P=0.1)
  Mean (SD) neonatal length (cm)          48.5 (3.0)     47.9 (3.5)     47.8 (2.9)                                                     0.6 (−1.2 to 0.1)† (P=0.10)                                   0.1 (−0.6 to 0.8)† (P=0.78)                                   0.7 (0.03 to 1.3)† (P=0.04)

\*Unless stated otherwise.

†Mean difference (95% CI).

As enrolment took place over a wide interval from 14 to 32 weeks of gestation, we assessed the relation between gestational age at enrolment and development of pre-eclampsia in women who received L-arginine and antioxidant vitamins compared with placebo. Treatment before 24 weeks reduced the incidence of pre-eclampsia (relative risk 0.37, 0.23 to 0.58), whereas treatment after 24 weeks did not (0.64, 0.30 to 1.37). However, when we estimated the interaction term between treatment effect and time of first treatment, we did not find it to be significant (B=0.002; P=0.96)

Secondary end points
--------------------

The overall rate of preterm birth was also reduced in women randomised to L-arginine plus antioxidant vitamins, although this was not because of a reduction in spontaneous preterm births (preterm premature rupture of membranes or preterm labour) (table 3[](#tbl3){ref-type="table"}). We found no difference in mean birth weight or in the proportion of small for gestational age infants. Other obstetrical complications, including placental abruption and postpartum haemorrhage, were similar among treatment groups. No maternal deaths occurred. Five neonatal deaths occurred in the study, two in the placebo group and three in the vitamins group. These deaths were associated with extreme prematurity. We found no differences in plasma concentrations of L-arginine between treatment groups at the beginning of the study.

The mean plasma concentration of L-arginine was lower at the first visit in women who later developed pre-eclampsia (20.5, SD 8.3) compared with those who did not develop pre-eclampsia (22.6, SD 8.8) (mean difference 2.01, 95% confidence interval 0.49 to 3.68; P\<0.01). The figures in the web appendix show the concentrations of L-arginine (fig A) and the diastolic and systolic blood pressures (fig B) in the different treatment groups. L-arginine concentrations were highest in the group receiving bars containing L-arginine, and the diastolic and systolic pressures were also significantly lower after initial treatment and negatively correlated with L-arginine plasma concentrations.

Discussion
==========

We observed a significant reduction in the incidence of pre-eclampsia/eclampsia in pregnant women who consumed bars containing L-arginine plus antioxidant vitamins. The results of this trial support the proposed hypothesis that supplemental L-arginine can reduce the risk of pre-eclampsia. Consistent with the main study outcome, a secondary finding of the study was that the L-arginine plus antioxidant vitamin supplementation resulted in a significant reduction in the risk of indicated preterm birth compared with placebo.

Methodological considerations and strengths
-------------------------------------------

Endothelial nitric oxide synthase is constitutively expressed in endothelial cells, and its activity depends on the level of expression of the enzyme, availability of the substrate, and concentrations of at least three different inhibitors that have been associated with pre-eclampsia. Synthesis of nitric oxide thus depends on the circulating concentration of L-arginine, and adaptive synthesis of nitric oxide in the endothelium is linked to dietary consumption of this amino acid. Our central hypothesis was that impaired vasodilatation in pregnancies complicated by pre-eclampsia could be prevented by supplementation with L-arginine in the diet. The existing literature suggests that L-arginine has direct effects on blood pressure in experimental animal models, normal humans, hypertensive patients, women with pre-eclampsia, and healthy pregnant women.[@ref14] [@ref15] [@ref16] [@ref17] [@ref18] [@ref19] [@ref20] [@ref21] [@ref22]

Consistent with recent research, antioxidant vitamins alone did not show a statistically significant reduction in the incidence of pre-eclampsia/eclampsia in our study. Adding L-arginine to antioxidant vitamins resulted in significant protection against the development of pre-eclampsia/eclampsia. Our trial was not powered to detect the small difference we found between the group consuming L-arginine plus antioxidant vitamins and the group consuming bars containing only vitamins. An intriguing result is that supplementing antioxidant vitamins had a statistically significant effect on reducing mild pre-eclampsia. This finding is not consistent with the pooled results of the other clinical trials of antioxidant vitamins, which do not suggest a benefit from treatment.[@ref30] Recently, the National Institutes of Health's Maternal-Fetal Medicine Units completed a large trial including several institutions in the United States, which reached a similar conclusion.[@ref31] In addition, detrimental effects of supplemental vitamin C and vitamin E during gestation have been reported.[@ref30] [@ref38] [@ref39]

Limitations of study
--------------------

The intervention used in this study must be evaluated in a population of pregnant women at low risk of pre-eclampsia. This is particularly relevant because we found a high prevalence of recurrence of pre-eclampsia in the studied population. Unfortunately, no information is available from other Mexican centres that could help to identify characteristics associated with this high recurrence rate compared with centres in other countries that have reported lower recurrence of pre-eclampsia.[@ref40] [@ref41]

At the time we started this clinical trial, no other commercial presentation for L-arginine was available other than supplemented bars. However, new products containing the amino acid L-arginine in a more palatable presentation are emerging. This makes it feasible to propose a population based study of L-arginine supplementation in larger groups of women with different levels of risk for pre-eclampsia. We did not include a study arm that consumed only L-arginine, as the producer could not supply such bars. In addition, we were aware that L-arginine metabolites may produce deleterious free radicals,[@ref42] so we considered the inclusion of antioxidant vitamins in the same bars to be beneficial. Unfortunately, our study design could not define the relative contributions of L-arginine and antioxidant vitamins to the beneficial effect of the combination on risk of pre-eclampsia. These ingredients may have had additive effects, or the interaction may have been synergistic. Further studies are needed to clarify these relations. Additionally, our trial was powered to detect a 50% reduction in pre-eclampsia and was thus not designed to detect smaller differences in risk reduction between L-arginine plus antioxidant vitamins and antioxidant vitamins alone.

We did not find concerning side effects during the supplementation of bars. However, caution is needed in women with peptic ulcer disease, as administration of L-arginine may worsen their symptoms.

The protective effect for pre-eclampsia may be greatest if L-arginine and antioxidant vitamins are supplemented before 24 weeks of gestation. Although our study design did not allow a rigorous test of time of supplementation and outcome, the above noted trend should be considered in the design of future clinical trials to evaluate the efficacy of L-arginine supplementation.

Study in context of previous studies
------------------------------------

Previous attempts to use L-arginine during pregnancy were designed to modify the course of established disease, using the amino acid as a hypotensive agent.[@ref43] Staff et al showed no effect of L-arginine on clinical course when used in women with pre-eclampsia beyond 28 weeks of gestation.[@ref44] This is in concert with our findings, in which women who started treatment beyond 24 weeks of gestation did not seem to benefit from treatment. Another clinical trial showed no benefits of arginine supplementation once the disease was established.[@ref45] However, preliminary evidence indicates that supplementing L-arginine during pregnancy may reduce the risk of pre-eclampsia. Germain et al disclosed some initial findings in women at high risk of pre-eclampsia who received L-arginine from week 10 of gestation.[@ref46] A small clinical trial of L-arginine supplementation in women with chronic hypertension that showed some maternal benefit was published after we submitted our work for publication, supporting the potential benefits of this intervention.[@ref47]

Conclusions
-----------

Our observations are consistent with the notion that availability of the substrate for nitric oxide synthesis (L-arginine) prolongs the latency to development of pre-eclampsia in a high risk population of women taking the amino acid supplement in the presence of antioxidant vitamins in a medical food. This relatively simple and low cost intervention may have value in reducing the risk of pre-eclampsia and associated preterm birth.

### What is already known on this topic

1.  Pre-eclampsia has been shown to be associated with defective vasodilatation

2.  Defective synthesis of nitric oxide, a key vasodilator, has been documented in pre-eclampsia

3.  Experimental data in animals and humans indicate that supplementation with L-arginine, the substrate for nitric oxide synthase, has a beneficial effect on arterial pressure

### What this study adds

1.  In a population of women at high risk of pre-eclampsia, dietary supplementation with L-arginine and antioxidant vitamins reduced occurrence of the disease

2.  Supplementation with antioxidant vitamins alone did not reduce occurrence of pre-eclampsia, consistent with previous studies

3.  Further study is needed to determine whether these results can be replicated and to identify whether they are due to L-arginine alone or the combination of L-arginine and antioxidant vitamins
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